These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Mechanisms of vasoactive intestinal peptide-mediated vasodilation in human skin. Wilkins BW; Chung LH; Tublitz NJ; Wong BJ; Minson CT J Appl Physiol (1985); 2004 Oct; 97(4):1291-8. PubMed ID: 15155712 [TBL] [Abstract][Full Text] [Related]
48. Enhanced anticancer activity in vitro and in vivo of luteolin incorporated into long-circulating micelles based on DSPE-PEG2000 and TPGS. Yan H; Wei P; Song J; Jia X; Zhang Z J Pharm Pharmacol; 2016 Oct; 68(10):1290-8. PubMed ID: 27465923 [TBL] [Abstract][Full Text] [Related]
49. Coronary vascular effects of vasoactive intestinal peptide in the isolated perfused rat heart. Sawmiller DR; Henning RJ; Cuevas J; Dehaven WI; Vesely DL Neuropeptides; 2004 Oct; 38(5):289-97. PubMed ID: 15464194 [TBL] [Abstract][Full Text] [Related]
50. Lipid-derivatized poly(ethylene glycol) micellar formulations of benzoporphyrin derivatives. Zhang JX; Hansen CB; Allen TM; Boey A; Boch R J Control Release; 2003 Jan; 86(2-3):323-38. PubMed ID: 12526828 [TBL] [Abstract][Full Text] [Related]
51. Human VIP-alpha: a long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension. Onyüksel H; Séjourné F; Suzuki H; Rubinstein I Peptides; 2006 Sep; 27(9):2271-5. PubMed ID: 16621151 [TBL] [Abstract][Full Text] [Related]
52. Vasoactive intestinal peptide causes nitric oxide-dependent pulmonary vasodilation in isolated rat lung. Iwabuchi S; Ono S; Tanita T; Koike K; Fujimura S Respiration; 1997; 64(1):54-8. PubMed ID: 9044476 [TBL] [Abstract][Full Text] [Related]
53. Vasoactive intestinal peptide stimulates mucus secretion, but nitric oxide has no effect on mucus secretion in the ferret trachea. Kim JS; Okamoto K; Arima S; Rubin BK J Appl Physiol (1985); 2006 Aug; 101(2):486-91. PubMed ID: 16645189 [TBL] [Abstract][Full Text] [Related]
54. Transferrin receptor-targeted pH-sensitive micellar system for diminution of drug resistance and targetable delivery in multidrug-resistant breast cancer. Gao W; Ye G; Duan X; Yang X; Yang VC Int J Nanomedicine; 2017; 12():1047-1064. PubMed ID: 28223798 [TBL] [Abstract][Full Text] [Related]
55. Preparation and in vitro synergistic anticancer effect of vitamin K3 and 1,8-diazabicyclo[5,4,0]undec-7-ene in poly(ethylene glycol)-diacyllipid micelles. Wang J; Mongayt DA; Lukyanov AN; Levchenko TS; Torchilin VP Int J Pharm; 2004 Mar; 272(1-2):129-35. PubMed ID: 15019076 [TBL] [Abstract][Full Text] [Related]
56. Design and evaluation of micellar nanocarriers for 17-allyamino-17-demethoxygeldanamycin (17-AAG). Chandran T; Katragadda U; Teng Q; Tan C Int J Pharm; 2010 Jun; 392(1-2):170-7. PubMed ID: 20363305 [TBL] [Abstract][Full Text] [Related]
57. PGH(2)-TxA(2)-receptor blockade restores vasoreactivity in a new rodent model of genetic hypertension. Suzuki H; Ikezaki H; Hong D; Rubinstein I J Appl Physiol (1985); 2000 Jun; 88(6):1983-8. PubMed ID: 10846009 [TBL] [Abstract][Full Text] [Related]
58. Optimization of Weight Ratio for DSPE-PEG/TPGS Hybrid Micelles to Improve Drug Retention and Tumor Penetration. Jin Y; Wu Z; Li C; Zhou W; Shaw JP; Baguley BC; Liu J; Zhang W Pharm Res; 2018 Jan; 35(1):13. PubMed ID: 29302821 [TBL] [Abstract][Full Text] [Related]
59. Polymeric micelles and nanoemulsions as drug carriers: Therapeutic efficacy, toxicity, and drug resistance. Gupta R; Shea J; Scafe C; Shurlygina A; Rapoport N J Control Release; 2015 Aug; 212():70-7. PubMed ID: 26091919 [TBL] [Abstract][Full Text] [Related]
60. Human pancreatic polypeptide in a phospholipid-based micellar formulation. Banerjee A; Onyuksel H Pharm Res; 2012 Jun; 29(6):1698-711. PubMed ID: 22399387 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]